Saad A. Khan

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

Barbara Burtness, Kevin J. Harrington, Richard Greil et al. · The Lancet · 2019 · 3K citations · Full text

Neoadjuvant Therapy, Chemotherapy Versus Cetuximab, Medicine +7

Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial

Vivek Subbiah, Jürgen Wolf, Bhavana Konda et al. · The Lancet Oncology · 2022 · 384 citations · Full text

Thyroid Tumours, Medicine, Metronomic Therapy +9

Immune dysregulation in cancer patients developing immune-related adverse events

Shaheen Khan, Saad A. Khan, Xin Luo et al. · British Journal of Cancer · 2018 · 180 citations · Full text

Prevalence of Autoimmune Disease Among Patients With Lung Cancer

Saad A. Khan, Sandi L. Pruitt, Lei Xuan et al. · JAMA Oncology · 2016 · 175 citations · Full text

Allergy, Autoimmune Disease, Advanced Lung Disease +5

Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, <i>EGFR</i> –Mutant, Metastatic Nonsquamous Non–Small Cell Lung Cancer

James Chih‐Hsin Yang, Dae Ho Lee, Jong‐Seok Lee et al. · Journal of Clinical Oncology · 2024 · 123 citations · Full text